Compare UCTT & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | DVAX |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2004 | 2004 |
| Metric | UCTT | DVAX |
|---|---|---|
| Price | $25.33 | $10.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $32.50 | $26.50 |
| AVG Volume (30 Days) | 467.0K | ★ 1.9M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,110,600,000.00 | $330,514,000.00 |
| Revenue This Year | N/A | $23.23 |
| Revenue Next Year | $5.74 | $16.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.65 | ★ 26.73 |
| 52 Week Low | $16.66 | $9.20 |
| 52 Week High | $40.64 | $14.63 |
| Indicator | UCTT | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 45.28 |
| Support Level | $21.49 | $11.33 |
| Resistance Level | $25.73 | $11.58 |
| Average True Range (ATR) | 1.25 | 0.34 |
| MACD | 0.26 | -0.04 |
| Stochastic Oscillator | 73.20 | 0.00 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.